

High Risk Medication - Antidepressants

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.		
Member Name:	Prescriber Name:	
Member Number:	Fax: Phone:	
Date of Birth:	Office Contact:	
Line of Business: Medicare Advantage	NPI: State Lic ID:	
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	
REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize he life or health of the enrollee or the enrollee's ability to regain maximum function.		
Drug Name:		
Strength:		
Directions / SIG:		
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.		
Q1. Is this an initial request of a high-risk medication? If YES, go to 3. If NO, go to 2.		
☐ Yes	□ No	
Q2. Has the prescriber provided an explanation that the benefit continues to outweigh the potential risk of the high-risk medication?		
☐ Yes	□ No	
Q3. Is the patient 65 years of age or older? If YES, go to 4.		
☐ Yes	□ No	
Q4. Are chart notes attached documenting an explanation of the risk versus benefit which shows the benefit outweighs the potential risk for the use of the high-risk medication? If YES, go to 5.		
☐ Yes	□ No	
Q5. Has the prescriber provided an attestation of intent to monitor and address treatment-related adverse events? If YES, go to 6.		
□Yes	□ No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



High Risk Medication - Antidepressants

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Q6. If the patient is taking one or more additional anticholinergic medications (e.g., oxybutynin, meclizine, paroxetine, amitriptyline, dicyclomine) with the requested drug, has the prescriber determined that taking multiple anticholinergic medications is medically necessary for the patient? (Note: Use of multiple anticholinergic medications in older adults is associated with an increased risk of cognitive decline). If YES or not applicable, go to 7.		
☐ Yes	□ No	
Q7. Are chart notes attached documenting the patient has depression? If YES, go to 8. If NO, go to 9.		
☐ Yes	□ No	
Q8. Is there documentation of inadequate response, intolerance, or contraindication to at least two non-high risk alternatives medically accepted for the patient's diagnosis such as a SSRI, SNRI, bupropion, mirtazapine, or trazodone?		
☐ Yes	□ No	
Q9. Are chart notes attached documenting the patient has OCD or panic disorder? If YES, go to 10. If NO, go to 11.		
☐ Yes	□ No	
Q10. Is there documentation of inadequate response, intolerance, or contraindication to at least two non-high risk alternatives medically accepted for the patient's diagnosis such as a SSRI?		
□ Yes	□ No	
Q11. Are chart notes attached documenting the patient has fibromyalgia or neuropathic pain (from spinal cord injury, antineoplastic therapy, post-herpetic neuralgia, or neuropathy due to diabetes mellitus)? If YES, go to 12. If NO, go to 13.		
☐ Yes	□ No	
Q12. Is there documentation of inadequate response, intolerance, or contraindication to at least two non-high risk alternatives medically accepted for the patient's diagnosis such as duloxetine, gabapentin, or pregabalin?		
☐ Yes	□ No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



High Risk Medication - Antidepressants

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:	
Q13. Are chart notes attached documenting the patient has insomnia? If YES, go to 14. If NO, go to 15.		
☐ Yes	□ No	
Q14. Is there documentation of inadequate response, intolerance, or contraindication to at least two safer alternatives medically accepted for the patient's diagnosis such as trazodone, mirtazapine, doxepin 3 mg or 6 mg, or ramelteon?		
☐ Yes	□ No	
Q15. Are chart notes attached documenting the patient has anxiety? If YES, go to 16. If NO, go to 17.		
☐ Yes	□ No	
Q16. Is there documentation of inadequate response, intolerance, or contraindication to at least two non-high risk alternatives medically accepted for the patient's diagnosis such as an SSRI, SNRI, or buspirone?		
☐ Yes	□ No	
Q17. Are chart notes attached documenting the patient is using this medication for preventive treatment of episodic migraine? IF YES, go to 18. If NO, go to 19.		
☐ Yes	□ No	
Q18. Is there documentation of inadequate response, intolerance, or contraindication to at least two non-high risk alternatives medically accepted for the patient's diagnosis such as venlafaxine, metoprolol, propranolol, or topiramate?		
☐ Yes	□ No	
Q19. I have educated the member in regards to the risks of concurrent utilization of benzodiazepine and opioid therapy, and the member accepts these risks.		
☐ Yes	□ No	
Q20. I acknowledge, as the prescriber initiating or maintaining multiple anticholinergic medications, the risk of adverse event(s) associated with concurrent utilization.		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



High Risk Medication - Antidepressants

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Member Name:	Prescriber Name:
☐ Yes	□ No
Q21. If applicable, I have consulted with the other prescribers involved in concomitant anticholinergic therapy for this member.	
☐ Yes	□ No
Q22. Requested Duration:	
☐ 12 Months	☐ Other
Q23. Additional Information:	
Prescriber Signature	Date
	v2026

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document